Proteins and Peptides

03 Nov 2020 Higher Response Rates in RECIPE Randomized Controlled Trial of KRYSTEXXA® (pegloticase injection) Concomitantly Used with the Immunomodulator Mycophenolate Mofetil
03 Nov 2020 Aurinia Announces Outcome of AUDREY™ Clinical Trial in Dry Eye Syndrome
02 Nov 2020 Neuraly Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 2B Trial of NLY01 for Patients with Alzheimer’s Disease
30 Oct 2020 Protagonist Therapeutics Announces Advancement of Oral IL-23 Receptor Antagonists Program in Collaboration with Janssen
29 Oct 2020 Sanofi to evaluate the safety and efficacy of novel investigational candidate THOR-707 and KEYTRUDA® (pembrolizumab) in pursuit of establishing a new treatment option in oncology
28 Oct 2020 Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19
27 Oct 2020 Apellis and Sobi Enter Collaboration for Global Co-development and Ex-US Commercialization of Systemic Pegcetacoplan in Rare Diseases with Urgent Need for New Treatments
27 Oct 2020 BridgeBio Pharma and Affiliate Phoenix Tissue Repair Announce First Patient Dosing In Phase 2 Trial of Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
26 Oct 2020 Medicenna Presents Promising Preclinical Data on IL-2 and IL-13 Superkines at the EORTC-NCI-AACR Annual Meeting
21 Oct 2020 Oxeia Biopharmaceuticals, Inc. Announces Initiation Of Phase 2 Trial For OXE103 For The Treatment Of Concussions
21 Oct 2020 NeoImmuneTech Announces a Second Clinical Collaboration with Roche to Evaluate NT-I7 (efineptakin alfa) in Combination with PD-L1 checkpoint inhibitor in First-line Non-small Cell Lung Cancer
14 Oct 2020 Amolyt Pharma Doses First Subject in Phase 1 Clinical Trial of Parathyroid Hormone Analog, AZP-3601, for Hypoparathyroidism
14 Oct 2020 Revance Reports Positive Results from ASPEN-1 Phase 3 Trial of DaxibotulinumtoxinA for Injection in Cervical Dystonia
09 Oct 2020 Selecta Biosciences and IGAN Biosciences Enter into Research License and Option Agreement to Study Selecta’s ImmTOR™ Immune Tolerance Platform in Combination with IGAN’s IgA Protease for the Treatment of IgA Nephropathy
08 Oct 2020 Ocular Therapeutix™ Announces Topline Phase 1 Clinical Trial Results of OTX-CSI
08 Oct 2020 Pfizer Announces Positive Phase 3 Top-line Results for Once-Weekly Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency
04 Oct 2020 Apellis Announces New Analysis Demonstrating Targeted C3 Therapy Pegcetacoplan Slows Progression of Early Disease in Patients with Geographic Atrophy (GA)
02 Oct 2020 EMA accepts regulatory submission for avalglucosidase alfa, a potentially new standard of care enzyme replacement therapy for Pompe disease
02 Oct 2020 Codiak Initiates Patient Dosing in Phase 1/2 Clinical Trial of exoSTING™ for the Treatment of Solid Tumors
01 Oct 2020 Sobi and Selecta Biosciences announce topline data of SEL-212 from the phase 2 COMPARE study supporting the potential for important clinical improvement in patients with Chronic Refractory Gout
29 Sep 2020 Ocular Therapeutix™ Announces First Patients Dosed in Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease
29 Sep 2020 Ascendis Pharma A/S Announces Preliminary Six-Month Data from Open-Label Extension of Phase 2 PaTH Forward Trial and Files IND Amendment to Initiate Phase 3 PaTHway Trial of TransCon™ PTH in Adult Hypoparathyroidism
25 Sep 2020 NeoMatrix Announces Positive Topline Phase 1 Data for NMT-cP12
25 Sep 2020 Molecular Partners Presents Preclinical Data Supporting Tumor Localization Mechanism of its CD40 Agonist MP0317 at World Bispecific Summit
23 Sep 2020 First patient randomised in the phase 3 DISSOLVE clinical programme of SEL-212 for Chronic Refractory Gout

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up